Vasculitis & polymyalgia rheumatica
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study
Authors' conclusion
One year of TCZ monotherapy was effective in maintaining drug-free clinical remission in LV-GCA. Changes in PETVAS early after TCZ discontinuation may predict subsequent relapses.
Study context
- Population
- Patients with active large vessel-GCA (LV-GCA)
- Participants
- 17 patients
- Outcome
- Variation in PETVAS at week 78 vs baseline and vs week 52, and proportion with relapse-free clinical remission at week 78 and at end of follow-up
- Follow-up
- Week 78
Methodological details26-week observational follow-up after tocilizumab (TCZ) discontinuation
- 26-week observational follow-up after TCZ discontinuation
Main finding
As reported in the abstract
PETVAS change at week 78
PET vascular activity score (PETVAS) change vs baseline, mean
−6.6 (−9.5 to −3.7) (95% CI)
PETVAS change vs week 52 (6 months after TCZ discontinuation), mean
4.6 (0.7-8.5) (95% CI)
Observational data: associations, not effects.
Further findings
| Outcome | Values | Age and sex-adjusted HR (95% CI) | |
|---|---|---|---|
| Subsequent relapse per unit increase of PETVAS | 1.36 (0.92–2.00) | ||
| 0.512Age and sex-adjusted HR (log scale) |
| Outcome | Values |
|---|---|
| Relapse-free clinical remission · week 78 | TCZ 65% (95% CI 38–86) |
| Relapse-free clinical remission at end of follow-up · median 148 weeks from TCZ discontinuation | TCZ 47% (95% CI 23–72) |
- Relapse-free clinical remission: 11/17
- Relapse-free clinical remission at end of follow-up: 8/17
Original publication
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study. Rheumatology (Oxford). Published 16 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →